Warfarin Prevents Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy

• Status: Unknown status
• Trial end date: 2019-09-30
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether Warfarin Anticoagulation are effective and safe in Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients with Hypersplenism after Laparoscopic Splenectomy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yangzhou University
• Treatments: Aspirin; Calcium heparin; Dalteparin; Dipyridamole; Heparin; Heparin, Low-Molecular-Weight; Tinzaparin; Warfarin

Criteria

Inclusion Criteria:

• A clinical, radiological or histologic diagnosis of cirrhosis of any etiology

• Splenomegaly with secondary hypersplenism, Platelet count < 50*10^9/L

• No evidence of PVT or spleno-mesenteric thrombosis by ultrasound evaluation and angio-CT

• Informed consent to participate in the study

Exclusion Criteria:

• Hepatocellular carcinoma or any other malignancy

• Hypercoagulable state other than the liver disease related

• DRUGS- oral contraceptives, anticoagulation or anti-platelet drugs

• Base line INR >2

• Child-Pugh grade C

• Recent peptic ulcer disease

• History of Hemorrhagic stroke

• Pregnancy

• Uncontrolled Hypertension

• Age>75 yrs

• F2 varices with red whale marks or F3 varices

• Bleeding portal hypertension

• Human immunodeficiency virus (HIV) infection